Proteomic Changes of Osteoclast Differentiation in Rheumatoid and Psoriatic Arthritis Reveal Functional Differences

Orsolya Tünde Kovács1,2†, Eszter Tóth3†, Olivér Ozohanics4, Eszter Soltész-Katona2,5, Nikolett Marton6, Edit Irén Buzás1,7,8, László Hunyady2,5,9, László Drahos3, Gábor Turu2,5‡ and György Nagy1,10,11

1 Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary, 2 Department of Physiology, Semmelweis University, Budapest, Hungary, 3 Institute of Organic Chemistry, Eötvös Loránd Research Network, Research Centre for Natural Sciences, Budapest, Hungary, 4 Department of Biochemistry, Semmelweis University, Budapest, Hungary, 5 Eötvös Loránd Research Network and Semmelweis University (ELKH-SE) Laboratory of Molecular Physiology, Eötvös Loránd Research Network, Budapest, Hungary, 6 Department of Radiology, Medical Imaging Centre, Semmelweis University, Budapest, Hungary, 7 Eötvös Loránd Research Network and Semmelweis University (ELKH-SE) Immune-Proteogenomics Research Group, Budapest, Hungary, 8 Hungarian Centre of Excellence for Molecular Medicine - Semmelweis University (HCEMM-SU) Extracellular Vesicles Research Group, Budapest, Hungary, 9 Institute of Enzymology, Eötvös Loránd Research Network, Research Centre for Natural Sciences, Budapest, Hungary, 10 Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary, 11 Heart and Vascular Centre, Semmelweis University, Budapest, Hungary

*Correspondence: Gábor Turu turu.gabor@med.semmelweis-univ.hu
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship

Background: Osteoclasts play a crucial role in the maintenance, repair, and remodeling of bones of the adult vertebral skeleton due to their bone resorption capability. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with increased activity of osteoclasts.

Objectives: Our study aimed to investigate the dynamic proteomic changes during osteoclast differentiation in healthy donors, in RA, and in PsA.

Methods: Blood samples of healthy donors, RA, and PsA patients were collected, and monocytes were isolated and differentiated into osteoclasts in vitro using macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANK-L). Mass spectrometry-based proteomics was used to analyze proteins from cell lysates. The expression changes were analyzed with Gene Set Enrichment Analysis (GSEA).

Results: The analysis of the proteomic changes revealed that during the differentiation of the human osteoclasts, expression of the proteins involved in metabolic activity, secretory function, and cell polarity is increased; by contrast, signaling pathways involved in the immune functions are downregulated. Interestingly, the differences between cells of healthy donors and RA/PsA patients are most pronounced after the final steps of differentiation to osteoclasts. In addition, both in RA and PsA the differentiation is characterized by decreased metabolic activity, associated with various immune pathway activities; furthermore by accelerated cytokine production in RA.
Conclusions: Our results shed light on the characteristic proteomic changes during human osteoclast differentiation and expression differences in RA and PsA, which reveal important pathophysiological insights in both diseases.

Keywords: mass spectrometry, osteoclast, rheumatoid arthritis, psoriatic arthritis, proteomics

1 INTRODUCTION

Bone remodeling is an essential process maintained by osteoclasts, which can uniquely break down bone and calcified cartilage and osteoblasts, which form the new bone (1). Osteoclast precursors are formed from bone marrow-derived monocyte/macrophage progenitor cells when stimulated with M-CSF and in the presence of M-CSF and RANK-L, they differentiate further to mononuclear prefusion osteoclasts, which then fuse into polarized multinuclear osteoclasts. Both RANK-L and M-CSF are essential for the differentiation, activation, and survival of osteoclasts (2–5). Isolating monocytes from blood samples and differentiating them into osteoclasts in vitro is a widely used model in human osteoclast studies since they are morphologically and functionally similar to physiological osteoclasts (6, 7). In these studies, adherent conditions are also required besides the application of M-CSF and RANK-L (8). Other methods for obtaining osteoclasts for in vitro studies include the differentiation of the murine RAW264.7 cell line or murine bone marrow macrophage (BMM) cultures (9, 10). Lately, human-derived pluripotent stem cells are also being used (11).

Imbalance in the finely regulated osteoblast-osteoclast system plays a central role in the pathogenesis of several metabolic bone and systemic inflammatory diseases. Due to the complex interactions of the bone and the immune system, inflammation may accelerate/increase bone resorption via osteoclast activation. Local osteoclast activation is promoted by proinflammatory cytokines released during inflammation (TNF-α, IL-1, IL-6, IL-17, IL-23), by RANK-L produced by lymphocytes and fibroblasts, and by direct cell-cell interactions (12, 13). The production of IL-17 by Th17 lymphocytes is elevated in certain inflammatory conditions, which has a synergic effect with IL-1 and TNF-α (14). Consequently, osteoclasts and synovial fibroblasts in the joint can be activated. Therefore, inflammation is associated with local and systemic bone loss in inflammatory arthropathies e.g. rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

Mass spectrometry (MS)-based proteomics is widely used for the identification and quantification of proteins expressed in diverse biological samples, and to analyze the expression of the cell signaling pathway components. There are a few published articles regarding the proteomics of osteoclasts differentiated from murine precursor cell lines (15–21) and BMM cultures (22). Although the proteomics of isolated monocytes from human peripheral blood was also examined (23–25), as far as we know, there is no published data regarding the proteome of human blood-derived preosteoclasts and osteoclasts and there is little information about the molecular changes during human blood-derived osteoclast differentiation. Also, there is no available information about the differences in protein expression in osteoclasts derived from RA or PsA patients.

In this study, we aimed to analyze proteomic changes during human osteoclast differentiation in healthy donors, RA, and PsA patients. We identify pathways that characterize the protein expression changes during the process and describe key pathways which differ in patients with inflammatory arthropathies. Understanding the characteristics of the proteome changes may help to expand our knowledge about the pathomechanisms involved in these diseases.

2 MATERIALS AND METHODS

2.1 Patients

RA and PsA patients’ and healthy donors’ blood was collected in the rheumatology outpatient department of the Semmelweis University in the Hospital of Hospitaller Brothers of St. John of God (Budapest, Hungary). Patients were diagnosed with RA according to the 2010 ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) classification criteria (26), or with polyarticular PsA according to the CASPAR (Classification Criteria for Psoriatic Arthritis) classification criteria (27). Based on their DAS-28 (disease activity score calculator for RA) or DAPSA (disease activity in PsA score) disease activity scores, patients had low, moderate, or high disease activity, or were in remission. The national ethics committee approved the study and informed consent was obtained from each individual (approval number: 8490-2/2018/EÜIG). This work was accomplished following the Helsinki Declaration (28).

2.2 Chemicals and Reagents

Ficoll, MEM α, L-glutamine, and Penicillin–Streptomycin were obtained from Sigma (St. Louis, MO, USA). FBS, PBS, and trypsin-EDTA solutions were purchased from Gibco Laboratories (Gaithersburg, MD, USA). EasySep was obtained from StemCell Technologies (Vancouver, Canada), rh M-CSF, and rh RANKL were purchased from PeproTech (London, UK). Acetonitrile, water, formic acid, ammonium-bicarbonate, and sodium deoxycholate were obtained from Merck (Darmstadt, Germany). Methanol was purchased from VWR International (Debrecen, Hungary). Dithiothreitol, iodoacetamide, and TFA were purchased from Thermo Scientific (Waltham, MA, USA), and RapiGest SF surfactant was obtained from Waters (Milford, MA, USA). Trypsin/L-ys-C Mix and Trypsin Gold were purchased from Promega Corporation (Madison, WI, USA). All chemicals, reagents, and solvents were HPLC-MS grade.

2.3 In Vitro Osteoclast Culture

Human blood samples were collected into vacutainer EDTA tubes (Greiner Bio-One, Monsonmagyarvar, Hungary). PBMCs (peripheral blood mononuclear cells) were isolated via a Ficoll
density gradient (Sigma, St. Louis, MO, USA). CD14+ cells were isolated from PBMCs using a positive magnetic separation method (EasySep, StemCell Technologies, Vancouver, Canada) (29). After isolation, a third of the monocytes were immediately frozen in liquid nitrogen. Two-thirds of monocytes were cultured (1x10⁵ monocytes per well) in MEM α (Minimum Essential Medium α) (Sigma, St. Louis, MO, USA) with 10% FBS (Gibco Laboratories, Gaithersburg, MD, USA), 1% L-glutamine (Sigma, St. Louis, MO, USA), and 1% Penicillin–Streptomycin (Sigma, St. Louis, MO, USA) at 37°C and 5% CO₂ in a humidified atmosphere. Monocytes were incubated with 50 ng/mL rh M-CSF (macrophage colony-stimulating factor) for 24 h (PeproTech, London, UK). Thereafter the samples were stimulated with 50 ng/mL of both rh M-CSF and rh RANKL (receptor activator of nuclear factor κB ligand) (PeproTech, London, UK). From then the media was replaced every 3-4 days.

### 2.4 Protein Isolation

On day 1, we froze the monocytes in liquid nitrogen. On days 5 and 9 of culture, differentiating pre-osteoclasts and osteoclast cells were washed in phosphate-buffered saline (PBS, Gibco Laboratories, Gaithersburg, MD, USA) and lysed directly in the culture plate by adding trypsin-EDTA solution (Gibco Laboratories, Gaithersburg, MD, USA), then frozen in liquid nitrogen. Samples were stored at -80°C for further investigation.

### 2.5 Cell Lysis

Cells stored in the medium were centrifuged, and pellets were washed using an ammonium-bicarbonate buffer. Cells were lysed and proteins were reduced in 50 μL lysis buffer containing 2% sodium deoxycholate, 0.5% RapiGest SF surfactant, and 100 mM dithiothreitol, heated 60°C for 30 min and sonicated as well as vortexed for 10 cycles (10 x 1 min). Protein concentration of the supernatant was measured using NanoDrop™ 1000 (Thermo Scientific, Waltham, MA, USA) as 5-15 mg/mL for most of the samples. If the concentration was >15 mg/mL, an additional 50 μL of lysis buffer was added to the samples.

### 2.6 Proteomic Analysis

Samples containing 2.5 nmol protein were first alkylated and digested with LysC and trypsin for 4 hours, then they were analyzed using a Dionex UltiMate 3000 RSLCnano system (Sunnyvale, CA, USA) coupled with a Maxis II QTOF mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Protein identification, quantification was performed using the Byonic v3.8.18 (https://proteinmetrics.org) and MaxQuant v1.6.17 (https://maxquant.org) software respectively. Detailed methodology – including missing data imputation and differential expression statistics – is described in the methodological supplementary.

### 2.7 Data Analysis

#### 2.7.1 Gene Set Enrichment Analysis (GSEA)

For the analysis, the protein names were first translated to gene names using the BioMart package in R, and with the help of the msigdbr and piano packages, the gene set enrichment was calculated using the https://www.gsea-msigdb.org/gsea/msigdb database. Specifically, we used GO Biological Process and GO Cellular Component ontology gene sets (C5) with ‘fsgea’ geneSetStat parameter.

#### 2.7.2 Plots and Statistics

The plots were created in python using matplotlib (D. Hunter, “Matplotlib: A 2D Graphics Environment”, Computing in Science & Engineering, vol. 9, no. 3, pp. 90-95, 2007.) and seaborn (seaborn: statistical data visualization Journal of Open Source Software) libraries. For the evaluation of the clustering performance to separate the samples based on the selected feature, we calculated the Hubert-Arabie adjusted Rand index (30) using the adjusted_rand_score function from the sklearn library.

### 3 RESULTS

#### 3.1 Proteome Changes During the Development of the Osteoclasts

To investigate the dynamic proteomic changes during osteoclast differentiation, we used the methodological process shown in Figure 1. First, blood samples of six healthy donors and six RA and six PsA patients were collected (Table 1). Monocytes were isolated from PBMCs by using a positive magnetic separation, then were cultured as described (31). Cells were differentiated into pre-osteoclasts and osteoclasts, which were collected on days 5 and 9. A total of 18 individual proteomic analyses were performed corresponding to the day 1, 5, and 9 of differentiation using 6-6-6 biological replicates of RA, PsA, and control samples. We identified a total of 1435 proteins (Supplementary Table 1) across 18 samples. For further analysis, we used the log2 transformed imputed LFQ values (Supplementary Table 2).

First, we compared the samples using principal component analysis (PCA) dimensionality reduction to study which parameters have the most pronounced effect on the expression changes during differentiation. As shown in Figure 2, the clustering of the samples overlaps largely with the different stages of the differentiation. To quantify the effect of the differentiation on the clustering, we clustered the samples using the k-means clustering algorithm and the results with the sample labels using the adjusted Rand score index (32). Differentiation stage-based classification overlapped with the k-means clusters with a score of 0.89. On the other hand, neither the date of experiment, donor’s age, laboratory parameters (RF, anti-CCP, CRP, ESR), duration of disease, or DAS-28 score (Supplementary Figure 1) had any significant effect on the clustering of the samples. Our data show that the samples clearly separate from each other based on their cell type. The PCA analysis also suggests that there is a substantially bigger difference between the pre-osteoclasts (differentiation day 5) and monocytes (day 1) than between the pre-osteoclasts and osteoclasts (Figure 2A). This is also shown in Figures 2D-F, where the expression changes are plotted against the log p values. These findings are consistent with the osteoclast differentiation process, in which monocytes are gradually transformed first to preosteoclasts, and then to osteoclasts.
Next, we compared the localization information of the detected proteins of all samples using the Uniprot database. The proteins that were detected were localized primarily to the cytoplasm, cell membrane, endoplasmic reticulum membrane, nucleus, and mitochondria (Figure 3A). To gain an overall insight into the proteomic changes during the osteoclast development, we compared the changes in expression in three pairs of samples (osteoclasts vs. monocytes, pre-osteoclasts vs. monocytes, and osteoclasts vs. pre-osteoclasts). There are robust changes in the expression of proteins during the differentiation (Figure 3). Similar to the previously reported changes on the RAW264.7 cell line (33), there is increased expression of mitochondrial proteins, and decreased expression of nuclear proteins of osteoclasts compared to the monocytes (left lane). As expected from the transition of the non-polarized monocytes to polarized osteocytes, the expression of the apical proteins is enhanced (Figure 3B) (34, 35).

Next, we applied enrichment analysis to the differential expression data of all samples. Specifically, we compared the enrichment of the proteins based on their localizations (GO cellular compartment, GO-CC) and biological processes (GO-BP). As shown in Figure 3 and Supplementary Table 3, the expression of the different secretory vesicle proteins was decreased, while the basolateral membrane proteins were enriched in the osteoclast/preosteoclast group. Moreover, the proteins localized to the ribosomes were enriched during the later phase of the differentiation. In line with the transition from an immune cell to a bone-resorbing cell type, the expression of proteins in the MHC cellular compartment is also decreased. Furthermore, if we compare the changes in biological processes, the osteoclasts show enrichment of proteins involved in osteoclast differentiation and carbohydrate metabolism, while the processes involved in the immune functions of the monocytes, e.g. migration, cytokine production, and various

### Table 1 | Basic patient characteristics.

| Donor | Diagnosis | Sex | Age (year) | DAS-28/DAPSA | Duration of disease (months) | CRP  | ESR | RF | anti-CCR | Therapy |
|-------|-----------|-----|------------|--------------|-------------------------------|------|-----|----|----------|---------|
| 1     | RA        | male | 87         | 2.4          | 43                            | 2.15 | 7   | -- | --       | methotrexate |
| 2     | RA        | female | 52     | 4.6          | 37                            | 0.3  | 2   | -- | --       | lefunomide, chloroquine |
| 3     | RA        | female | 67     | 2.2          | 75                            | 0.5  | 18  | 97 | 404      | methotrexate, chloroquine |
| 4     | RA        | female | 56     | 2.0          | 29                            | 1.2  | 5   | 41 | --       | methylprednisolone, methotrexate |
| 5     | RA        | female | 66     | 0.6          | 255                           | 0.7  | 2   | 128 | 287      | methotrexate |
| 6     | RA        | female | 80     | 3.9          | 267                           | 15   | 38  | 200 | 436      | methylprednisolone, methotrexate |
| 1     | PsA       | female | 61     | 3.5          | 0                             | 11   | --  | -- | --       | --       |
| 2     | PsA       | female | 73     | 3.1          | 65                            | 4.9  | 12  | -- | --       | methotrexate |
| 3     | PsA       | female | 54     | 3.2          | 141                           | 1.5  | 11  | -- | --       | methotrexate |
| 4     | PsA       | male   | 74     | 4.0          | 129                           | 4    | 2   | -- | --       | methotrexate, chloroquine |
| 5     | PsA       | female | 45     | 5.0          | 153                           | 2.99 | 2   | -- | --       | methotrexate |
| 6     | PsA       | male   | 41     | 5.3          | 46                            | 2.3  | 5.3 | -- | --       | methotrexate |

Blood samples from 6 patients with RA and 6 with PsA were included in the experiments. Basic characteristics are listed. DAS-28, disease activity score calculator for rheumatoid arthritis; DAPSA, disease activity in psoriatic arthritis score; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide autoantibody.

FIGURE 1 | Methodological process. Blood was collected from healthy donors and RA and PsA patients. Monocytes were isolated from PBMCs, then differentiated to preosteoclasts and osteoclasts. Samples were collected, then prepared for proteomic analysis. HPLC-MS/MS analysis was carried out, finally data were analyzed.
proteins in immune responses are downregulated (Figure 3 and Supplementary Table 3) (33, 36). The expression of basolateral proteins (besides apical proteins in Figure 3B) is enhanced as well (Figure 3). (30, 31).

To have a deeper look at the main differences between osteoclast and monocyte samples, we have selected two biological processes, one of which is enhanced and one of which is decreased), and depicted the involved proteins in Figures 4, 5 (Supplementary Table 4). Monosaccharide metabolic processes in osteoclast samples are increased in line with the elevated metabolic demands of these secretory cells (Figures 4A). On the other hand, proteins involved in the defense response to bacterium pathway are decreased in line with the transition during differentiation from monocytes into osteoclasts (Figures 5A). These include mainly secreted proteins, like cathepsin G and haptoglobin, but also some vesicular ones like myeloperoxidase.

Looking at the individual proteins, the biggest expression changes in the osteoclasts (over 10 fold differential expression changes) are connected to their transition from an immune cell to a cell type with a high level of metabolism and secretion and downregulated immune-function related proteins (Supplementary Table 5). The proteins with the highest differential expression in the osteoclasts compared to monocytes are mostly the ones that have been previously reported in the literature as some of the characteristic proteins in these cells. The increased metabolism is characterized by the overexpression of the transferrin receptor protein 1 (required for mitochondrial respiration) (37). Creatine kinase B-type plays a central role in tissues with large energy, as it catalyzes the transfer of phosphate between phosphagens and ATP, and was found to be markedly induced in mature osteoclasts (19) and has a key role in osteoclast-mediated bone resorption (19, 38).

The increased osteoclast-specific secretion is supported by the increased expression of vacuolar-type H⁺-ATPase (V-ATPase), sodium/hydrogen exchanger 9B2 (a Na⁺/H⁺ antiporter) (39, 40), cathepsin K and B (proteolytic enzymes) (41, 42), and lysosomal acid phosphatase (43). Integrin alpha-V crossing the cell membrane and anchored to the bone surface is essential, with which osteoclasts come into close contact with bone and promote the formation of the resorption lacunae (44). These results show, that the proteins with increased expression in osteoclasts detected in our experiments fit well with the previously reported characteristics of these cells.

Most of the proteins which are strongly downregulated in healthy osteoclasts play an important role in immune responses (e. g. complement receptor type 1), or in inflammatory processes (e. g. protein S100-A8), or have an antiviral (e. g. neutrophil defensin 1) or an antimicrobial (e. g. lysozyme C) effect. Platelet glycoprotein Ib beta chain is important in blood coagulation, while Annexin A3 is an anticoagulant. Some proteins (e. g. intercellular adhesion molecule 3) play a role in cell adhesion and phospholipase B-like 1 in lipid metabolism. Myeloid cell nuclear differentiation antigen is a transcription regulator. Some proteins (e. g. interferon-induced transmembrane protein 2) have a role in innate immunity, some in adaptive immunity (e. g. immunoglobulin kappa constant), while ficolin-1 in both (Supplementary Table 5).

3.2 Differences Between Healthy Control and Patient Samples Manifest During Osteoclast Development

In certain autoimmune diseases, like RA and PsA, activation of osteoclast cells is increased as a result of the inflammation, which promotes the production of TNF and RANK-L. Increased osteoclast activation fosters pathological bone destruction, such
as the erosion of the bone and cartilage, leading to focal osteolysis of the inflamed joints. Therefore, we next investigated if there are differences in protein expression in osteoclasts originating from healthy subjects and those from patients with RA or PsA. As shown in Figure 2C, diagnoses did not have a significant impact on the clustering of the samples, when all cell types were included in the analysis. Therefore, we tested whether the differences are more pronounced if the samples are clustered within cell types. Surprisingly, as shown in Figure 6, we could detect separation of the cells with PCA analysis only when the cells were fully differentiated, but not when the monocytes were compared, suggesting that these diseases had overall more significant effects on the protein expressions of the osteoclasts than in monocytes.

The Rand index score generated by the cluster strength algorithm was increased during cell differentiation, reaching a 0.43 value in the case of osteoclast samples. Surprisingly, these findings suggest that when monocytes are isolated from the blood of healthy donors and RA or PsA patients and differentiated in vitro under the same circumstances, differences between healthy and unhealthy samples still manifest in more mature stages of cell development.

3.3 RA and PsA Osteoclasts Show Increased Expression of Proteins Involved in Immunological Processes

Since the largest differences between healthy and unhealthy samples were found in osteoclasts, we focused on these cells during the enrichment analysis of the RA and PsA samples. Figure 7 and Supplementary Table 6 show the enriched cellular compartments and biological processes, respectively, in which the RA samples significantly differ from the healthy ones. Interestingly, the RA and healthy osteoclasts show marked differences regarding to protein cellular compartments and biological processes. Regarding the compartments, most changes are related to different membrane compartments, most likely pointing to changes in vesicular trafficking (Figure 7). Interestingly, some of the proteins involved in the ATP biosynthetic processes were decreased, while proteins playing role in immunological processes were increased, like the antigen-presenting MHC-I and MHC-II proteins (Figures 7, 8). These data suggest, that osteoclasts differentiated from the RA patients’ monocytes fail to fully adapt to the increased metabolic demand found in healthy osteoclasts and retain some of their immunological functions. One explanation of these proteome
characteristics in RA osteoclast could be a different rate of differentiation, resulting in a higher proportion of undifferentiated cells at the end of the experiments. To explore this possibility, we have created a series of weighted protein level averages of osteoclasts and either monocytes or preosteoclasts to simulate a mixture of cells. When we have averaged these proteins from non-osteoclast samples with weights between 0 and 1 with those from osteoclasts (with a weight of 1), the clustering of the healthy and RA samples still clustered in different groups when checked with PCA analysis (Figure 2).

This suggests that even if some of the differences might stem from the slower rate of differentiation in either of the samples, this does not fully explain the detected phenotypes.

In the case of the PsA samples, proteins localized to Golgi, endosomes, several types of endocytic and phagocytic vesicles and granules, endoplasmatic reticulum, and MHC protein complexes (Figure 7 and Supplementary Table 6). In addition, several processes involved in immunological functions, like antigen presentation, response to bacterium, positive regulation of adaptive immune response, and positive regulation of lymphocyte responses were increased in PsA samples (Figures 7, 9). On the other hand, the expression of ribosomal, nuclear, and chromosome proteins, connected to organelle organization, metabolic processes, cytoskeleton, transcription, and translation was decreased (Figures 7, 9).

4 DISCUSSION

Mass spectrometry (MS)-based proteomics is widely used for the identification and quantification of proteins expressed in biological samples (15–21). Although in addition to the physiological bone remodeling, osteoclasts play a central role in the pathogenesis of both RA and PsA, the detailed in vitro
proteomic analysis of osteoclastogenesis from monocytes was not investigated yet. Previous proteomic studies on the one hand investigated mice originating from BMM cultures, which can be differentiated into osteoclasts in 3 days (22). On the other hand, the majority of the murine studies focused on the RAW264.7 cell line, which is a monocyte/macrophage osteoclastogenesis model; can be committed to pre-osteoclasts in 2 days and to osteoclasts in 3 days (17). The proteomics of human blood-derived monocytes was also studied (without further differentiation to osteoclasts) (23–25).

**FIGURE 5** | Depiction of proteins significantly expressed in monocytes. (A): The density curve and individual protein differential expression log2 values of protein expressions in the defense response to bacterium pathway identified in osteoclasts. (B): drawing represents the most significantly expressed proteins involved in defense response to bacterium in monocyte samples compared to osteoclast samples. Blue filling shows downregulation of proteins in osteoclast samples compared to monocytes. The full table with p values are provided in Supplementary Table 4.

**FIGURE 6** | Healthy, RA or PsA samples vary mostly in osteoclast state. PCA analysis representing the differences between healthy, RA or PsA samples in (A) monocytes, (B) preosteoclasts and (C) osteoclasts.
FIGURE 7 | Protein expression differences of RA and PsA samples compared to healthy samples. Heat maps representing the sample protein localizations (A, C), or functions (B, D) analyzed with protein GSE using GO: Cellular Compartments (A, C) and Biological Process terms (B, D) for RA versus healthy (A, B), or PsA versus healthy (C, D) samples. Terms with the smallest adjusted p-values are shown on the heat-map. Not all terms are indicated on the y-axis, the full table with p-values are provided in Supplementary Table 6.

FIGURE 8 | Depiction of proteins significantly expressed in osteoclasts of RA donors. Proteins with blue frame represent proteins of ATP biosynthetic processes pathway, proteins with red frame represent proteins of regulation of T cell mediated cytotoxicity pathway. Blue filling shows downregulation of proteins in RA osteoclast samples compared to healthy ones, red filling shows upregulation of proteins.

FIGURE 9 | Depiction of proteins significantly expressed in osteoclasts of PsA donors. Proteins with blue frame represent proteins of cytoplasmic translation pathway, proteins with red frame represent proteins of positive regulation of adaptive immune response pathway. Blue filling shows downregulation of proteins in PsA osteoclast samples compared to healthy ones, red filling shows upregulation of proteins.
Here for the first time, we report the proteomic changes during human blood-derived osteoclastogenesis of healthy donors’ as well as in RA and PsA. According to our present data, mitochondrial proteins were upregulated, whereas nuclear proteins, secreted proteins, and proteins involved in diverse immune functions were downregulated during osteoclastogenesis of healthy donor-derived monocytes (Figure 3). Eunkyung An et al. also found increased mitochondrial protein expression during the differentiation of RAW264.7 cells into osteoclasts (33). These findings are consistent with the high energy demand of bone resorption activity (33, 38). Interestingly, unlike monocytes, osteoclasts of healthy, RA, or PsA samples could be well discriminated based on their protein expression (Figure 6). Both in RA and PsA osteoclasts, the expression of proteins involved in immunological processes and proteins of the MHC complex was increased compared to healthy samples (Figure 7). The expression of proteins involved in ATP synthesis is decreased in RA osteoclasts, whereas processes involved in protein synthesis are downregulated in PsA samples. A decrease in protein synthesis might signal redirection of the cellular resources to other demanding processes, which in this case could be the enhanced immunological processes and intensive vesicular transports. The link between lipid oxidation and psoriasis was recently studied (45). Proteins involved in metabolic processes (e.g. mitochondrial import receptor subunit TOM6 homolog) were decreased in samples of both RA and PsA compared to healthy osteoclasts (Figure 7). The small number of healthy, RA, or PsA donors is a limitation in our present study. It has to be also noted, that the applied model in this experiment system does not fully model the native osteoclast differentiation when osteoclasts differentiate from local precursors, not from monocytes circulating in the blood.

RA and PsA may have similar symptoms and similarities in their pathomechanism. Serologic analysis shows the main differences between these two diseases; 70-80% of RA patients are seropositive for RF (rheumatoid factor) and/or anti-CCP (cyclic citrullinated peptide) autoantibody, while most of the PsA patients are RF and/or anti-CCP negative. Predisposing genetic factors also differ in these diseases; the presence of HLA-B27 and HLA-DRA alleles predispose PsA, while the HLA-DRB1 allele (46) and single nucleotide polymorphism of the PTPN22 gene (47) predispose RA. There are also main differences in the development of pathology of these two diseases. In RA IL-1 and IL-6, RANK-L and ACPA (anti-citrullinated protein antibodies) are associated with the induction of osteoclastogenesis, and the number of T- and B-cells is higher in the inflamed synovial tissue in RA than in PsA (48–50). IL-17 and IL-23 cytokines in turn have a more dominant role in PsA disease development, and the number of T-helper 17 cells is higher in PsA than in RA (51). TNF-α inhibitors and JAK inhibitors are beneficial in both RA and PsA. Inhibition of IL-1 and IL-6 cytokines, B-cells or T-cells, is beneficial in RA; while inhibition of IL-12/23 and IL-17 have therapeutic efficacy in PsA (52). These differences in the cytokine environment might result in altered expression profiles in differentiated osteoclasts themself, or alternatively, might inhibit the differentiation process and lead to remaining immunological functions in these cells. Since the differences are more pronounced after differentiation, the latter option could seem more likely. However, when the protein levels of the osteoclasts are corrected with weighted averaging with those of the precursors, the clustering of the samples does not disappear, suggesting that the different rate of the differentiation itself does not explain all the differences detected. More likely, the monocytes derived from patients with RA or PsA differentiate to osteoclasts, but some of the antigen-presenting and other immune processes remain. Interestingly, it has been reported, that Hsp90α protein expression promotes osteoclast differentiation through regulation of the PPARγ pathway (53). In our samples, both Hsp90α and Hsp90β expressions were decreased, which is in agreement with the impaired transition of these cells from immune cells into osteoclasts. Nevertheless, in both RA and PsA, the bone erosions may be present, although in RA they mainly appear in peripheral joints and show symmetric involvement, while in PsA they may appear in both peripheral and axial joints and generally show asymmetric involvement. These bone erosions are in line with our results that suggest that osteoclasts in these diseases might keep some of their immune cell functions.

In summary, this is the first human study that examines the detailed proteomic changes during human osteoclast differentiation. Based on our results, protein expression differences between RA and PsA osteoclasts reveal immune and other functional differences in these diseases. Further studies with a higher number of patients including different disease stages (e.g. pre-RA or difficult-to-treat RA (54)) will provide future data regarding osteoclastogenesis in inflammatory arthropathies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: https://doi.org/doi:10.25345/CSM61BT0F.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ministry of Human Resources, Budapest, Hungary. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LD, GN, GT, ET, and OK contributed to conception of the study. LD, ET, GT, NM, OK, and OO developed the methodology. ET, GT, OK, and OO performed formal analysis. ET, GT, OK, and OO performed data curation. GN, GT, and OK wrote the first draft of the manuscript. OK, ET, OO, NM, EB, LD, LH, GT, ESK and GN wrote sections of or edited the manuscript. GT and OK prepared the figures. GT, GN, and LH supervised the study. OK guided the project administration. LH, GT, and GN provided the funding ESK performed verification experiments. All authors contributed to manuscript revision, read, and approved the submitted version.
ACKNOWLEDGMENTS

We thank Bence Szalai for his variable insights.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.892970/full#supplementary-material

REFERENCES

1. Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ. Modeling the Interactions Between Osteoblast and Osteoclast Activities in Bone Remodeling. J Theor Biol (2004) 229(3):293–309. doi: 10.1016/j.jtbi.2004.03.023
2. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis. Biochem Biophys Res Commun (1998) 253(2):395–400. doi: 10.1006/bbrc.1998.9788
3. Asagiri M, Takayanagi H. The Molecular Understanding of Osteoclast Differentiation. Bone (2007) 40(2):251–64. doi: 10.1016/j.bone.2006.09.023
4. Miyamoto T. Regulators of Osteoclast Differentiation and Cell-Cell Fusion. Keio J Med (2011) 60(4):101–5. doi: 10.2302/kjm.60.101
5. Hodge JM, Kirkland MA, Nicholson GC. Multiple Roles of M-CSF in Human Osteoclastogenesis. J Cell Biochem (2007) 102(3):759–68. doi: 10.1002/jcb.21331
6. Bernhardt A, Bacova J, Gubarek U, Gelinsky M. Influence of Cu2+ on Osteoclast Formation and Activity. FEBS Lett (2005) 564(1-2):166–70. doi: 10.1016/j.febslet.2004.06.016
7. 35. doi: 10.1002/jbmr.4322
12. Yokota K, Sato K, Miyazaki T, Aizaki Y, Tanaka S, Sekikawa M, et al. Characterization and Function of Tumor Necrosis Factor and Interleukin-6-Induced Osteoclasts in Rheumatoid Arthritis. Arthritis Rheumatol (2021) 73(7):1145–54. doi: 10.1002/art.41666
13. Walsh MC, Choi Y. Biology of the TRANCE Axis. Cytokine Growth Factor Rev (2003) 14(3-4):251–63. doi: 10.1016/s1359-6101(03)00027-3
14. Paine A, Ritchlin C. Bone Remodeling in Psoriasis and Psoriatic Arthritis: An Update. Curr Opin Rheumatol (2016) 28(1):66–75. doi: 10.1097/BOR.0000000000000232
15. Heckel T, Czupalla C, Expósito Santo AI, Anitei M, Arantzu Sanchez-Fernandez M, Mosch K, et al. Src-Dependent Repression of ARF6 is Required to Maintain Podosome-Rich Sealing Zones in Bone-Digesting Osteoclasts. Proc Natl Acad Sci U S A (2019) 106(5):1451–6. doi: 10.1073/pnas.0804464106
16. Ryu J, Kim H, Lee SK, Chang E-J, Kim H-J, Kim H-H. Proteomic Identification of the TRAF6 Regulation of Vacular ATPase for Osteoclast Function. Proteomics (2005) 5(16):4152–60. doi: 10.1002/pmic.200402035
17. Chang E-J, Kwak HB, Kim H, Park J-C, Lee ZH, Kim H-H. Elucidation of CPX-1 Involvement in RANKL-Induced Osteoclastogenesis by a Proteomics Approach. FEBS Lett (2004) 564(1-2):166–70. doi: 10.1016/S0014-5793(04)00338-2
18. Ha BG, Hong JM, Park J-Y, Ha M-H, Kim T-H, Cho J-Y, et al. Proteomic Profile of Osteoclast Membrane Proteins: Identification of Na+/H+ Exchanger Domain Containing 2 and its Role in Osteoclast Fusion. Proteomics (2008) 8(13):2625–39. doi: 10.1002/pmic.200701192
19. Chen J, Sun Y, Mao X, Liu Q, Wu H, Chen Y. RANKL Up-Regulates Brain-Type Creatine Kinase via Poly(ADP-Ribose) Polymerase-1 During Osteoclastogenesis. J Biol Chem (2010) 285(47):36315–21. doi: 10.1074/jbc.M110.157743
20. Manes NP, Angermann BR, Koppenol-Raab M, An E, Spoelund VH, Sun J, et al. Targeted Proteomes-Driven Computational Modeling of Macrophage S1P Chemosensing. Mol Cell Proteomics (2015) 14(10):2661–81. doi: 10.1074/mcp.M115.048918
21. Freire MS, Cantuaria APC, Lima SMF, Almeida JA, Murad AM, Franco OL, et al. NanoUPLC-MS(E) Proteomic Analysis of Osteoclastogenesis Downregulation by IL-6. J Proteomics (2016) 131:18–16. doi: 10.1016/j.jprot.2015.10.004
22. Ryu J, Kim H, Chang E-J, Kim H-J, Lee Y, Kim H-H. Proteomic Analysis of Osteoclast Lipid Rafts: The Role of the Integrity of Lipid Rafts on V-ATPase
